Driehaus Capital Management LLC Acquires 17,913 Shares of TransMedics Group, Inc. $TMDX

Key Points

• Driehaus Capital Management LLC increased its stake in TransMedics Group, owning 778,754 shares valued at approximately $52.4 million, representing a 2.4% increase.
• A number of analysts have upgraded their ratings for TransMedics Group, with Oppenheimer raising the price target from $130 to $150 and maintaining an "outperform" rating.
• TransMedics Group reported a 37.7% increase in quarterly revenue year-over-year, achieving $157.37 million, significantly surpassing the consensus estimate of $146.64 million.

Driehaus Capital Management LLC raised its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 2.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 778,754 shares of the company's stock after acquiring an additional 17,913 shares during the period. Driehaus Capital Management LLC owned approximately 2.30% of TransMedics Group worth $52,395,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Smartleaf Asset Management LLC raised its position in shares of TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after acquiring an additional 135 shares during the last quarter. CWM LLC raised its position in shares of TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after acquiring an additional 155 shares during the last quarter. Campbell Newman Asset Management Inc. raised its position in shares of TransMedics Group by 1.4% during the 1st quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company's stock valued at $782,000 after acquiring an additional 166 shares during the last quarter. Hager Investment Management Services LLC raised its position in shares of TransMedics Group by 38.3% during the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after acquiring an additional 205 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in shares of TransMedics Group by 1.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 15,824 shares of the company's stock valued at $1,065,000 after acquiring an additional 256 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. Morgan Stanley upped their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Oppenheimer upped their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research report on Tuesday, June 17th. Piper Sandler restated an "overweight" rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Wall Street Zen cut shares of TransMedics Group from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Canaccord Genuity Group upped their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research report on Tuesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, TransMedics Group currently has a consensus rating of "Moderate Buy" and a consensus target price of $123.00.

TransMedics Group Stock Down 2.9%

NASDAQ TMDX traded down $3.27 on Wednesday, reaching $108.28. The company had a trading volume of 759,213 shares, compared to its average volume of 1,305,651. The firm has a market capitalization of $3.69 billion, a price-to-earnings ratio of 56.16 and a beta of 2.18. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $169.29. The company's fifty day moving average is $119.57 and its 200-day moving average is $103.65.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. During the same period in the prior year, the business posted $0.35 EPS. The company's quarterly revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. On average, research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the transaction, the insider directly owned 13,955 shares of the company's stock, valued at $1,950,909. This represents a 4.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.00% of the stock is currently owned by corporate insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.